Development of a Prediction Platform for Neoadjuvant Treatment and Prognosis in Pancreatic Cancer Using Organoid

NCT04777604 · clinicaltrials.gov ↗

UNKNOWN

Status

300

Enrollment

OTHER

Sponsor class

Conditions

Pancreas Cancer

Interventions

OTHER: Organoid

Sponsor

Samsung Medical Center